Dawson James Reaffirms Their Buy Rating on Collplant Holdings (CLGN)

In a report issued on December 27, Jason Kolbert from Dawson James maintained a Buy rating on Collplant Holdings (CLGNResearch Report), with a price target of $20.00. The company’s shares closed last Thursday at $13.82.

According to TipRanks.com, Kolbert is a 4-star analyst with an average return of 5.0% and a 41.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics.

Currently, the analyst consensus on Collplant Holdings is a Moderate Buy with an average price target of $20.00.

See the top stocks recommended by analysts >>

Based on Collplant Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $140K and GAAP net loss of $3.08 million. In comparison, last year the company earned revenue of $4.15 million and had a net profit of $703K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CollPlant Biotechnologies Ltd. is a regenerative medicine company. It engages in the research, development, manufacture and marketing of medical products for tissue repair, initially for orthobiologics and advanced wound care markets. The company’s products include VergenixSTR, VergenixFG, CollPlant Surgical Matrix. Collplant Holdings was founded by in June 2004 and is headquartered in Ness-Ziona, Israel.

Read More on CLGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed